Form 8-K - Current report:
SEC Accession No. 0001193125-17-170677
Filing Date
2017-05-15
Accepted
2017-05-15 16:23:07
Documents
6
Period of Report
2017-05-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 4.01: Changes in Registrant's Certifying Accountant
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d393884d8k.htm 8-K 50025
2 EX-3.1 d393884dex31.htm EX-3.1 7771
3 EX-3.2 d393884dex32.htm EX-3.2 4341
4 EX-10.1 d393884dex101.htm EX-10.1 108430
5 EX-16.1 d393884dex161.htm EX-16.1 5866
6 GRAPHIC g393884dsp043.jpg GRAPHIC 2311
  Complete submission text file 0001193125-17-170677.txt   181592
Mailing Address 19900 MACARTHUR BLVD. SUITE 550 IRVINE CA 92612
Business Address 19900 MACARTHUR BLVD. SUITE 550 IRVINE CA 92612 949-238-8090
Novus Therapeutics, Inc. (Filer) CIK: 0001404281 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36620 | Film No.: 17844536
SIC: 2834 Pharmaceutical Preparations